Drug class
Activated factor XII (FXIIa) inhibitor; fully human monoclonal antibody
Mechanism of action
Binds the catalytic domain of activated factor XII (FXIIa and βFXIIa) and inhibits its activity. This reduces activation of prekallikrein to kallikrein and subsequent bradykinin generation in the contact activation/kallikrein–kinin pathway.
General use cases
- Routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US ANDEMBRY indication (approved 16 June 2025); not for treatment of an acute HAE attack
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
